Autologous Blood for Full-thickness Macular Hole

Omer Othman Abdullah

Status: Terminated

Conditions: Ophthalmopathy

Treatments: Other: Pars-plana vitrectomy

Study type: Interventional

Funder types: Other

Identifiers

NCT05494229

IMER 111

Details and patient eligibility

About

Autologous blood for primary and recurrent holes

Full description

Utilizing whole autologous blood for closing both primary and recurrent holes. Here, we apply a drop of the taken whole blood over the hole, and the access blood will be aspirated on the macula with a silicon-tipped active back-flash cannula, to abolish all the possibilities of the fibrinogenic behavior of the whole blood composition, which might cause traction and recurrent hole formation. Therefore, only the hole will be filled with blood. The blood will be taken under completely sterile and aseptic conditions.

The air infusion will be raised after the valve of one of the trocars will be removed, to allow the air current to dry the clot inside the hole rapidly. Then air gas exchange will be performed to allow the clot to remain away from intraocular fluids for one to two weeks and abolish the possibility of the clot being dissolved.

Enrollment: 5 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Primary and recurrent holes

Exclusion criteria

• Lamellar and pseudoholes

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

5 participants in 1 patient group

Utilizing autologous whole blood for the full thickness macular hole

Experimental group

Description:

It is an interventional study by performing pars-plana vitrectomy

Treatment:

Other: Pars-plana vitrectomy